Form 4: Disc Medicine Director Kevin Bitterman Reports Acquisition of Shares and Potential Short-Swing Profit Liability

Director Kevin Bitterman reports acquiring Disc Medicine shares and a potential liability for short-swing profits due to a matchable purchase with prior sales by related entities.

Summary

• Kevin Bitterman, a director of Disc Medicine, Inc. [IRON], reported acquiring 222,223 shares of common stock on June 17, 2024, at a price of $36 per share.
• Following the transaction, Bitterman indirectly beneficially owns 420,549 shares through Atlas Venture Opportunity Fund II, LP, 677,503 shares through Atlas Venture Opportunity Fund I, LP, and 51,000 shares through Atlas Venture Fund XII, L.P.
• The reported purchase is matchable with prior sales of common stock by Atlas Venture Opportunity Fund I and II, entities in which Bitterman has a pecuniary interest, potentially resulting in short-swing profit liability under Section 16(b) of the Exchange Act.
• Bitterman has agreed with Disc Medicine to disgorge any short-swing profits attributable to his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the purchase of shares is generally positive, the potential short-swing profit liability introduces a negative element. The agreement to disgorge profits mitigates some of the negative sentiment.

Positives

• Bitterman's purchase of shares could be interpreted as a sign of confidence in Disc Medicine's future prospects.

Negatives

• The potential short-swing profit liability could raise concerns about compliance with securities regulations.
• The need to disgorge profits, even if attributable to a pecuniary interest, could negatively impact Bitterman's investment returns.

Risks

• The short-swing profit liability could lead to legal or regulatory scrutiny.
• The disgorgement of profits could set a precedent for similar situations in the future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing is notable due to the potential short-swing profit implications, which can arise when insiders buy and sell company stock within a six-month period.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The potential short-swing profit liability is not uncommon, particularly for individuals associated with investment funds that actively trade in company stock.
• Similar situations have occurred with directors and officers at companies like Moderna and BioNTech, where large stock holdings and frequent trading can trigger Section 16(b) violations.

Stakeholder Impact

• Shareholders may be concerned about the potential short-swing profit liability and its impact on Bitterman's alignment with their interests.
• The company's reputation could be slightly affected by the disclosure of the short-swing profit issue.

Next Steps

• Bitterman will need to calculate and disgorge any short-swing profits to Disc Medicine.
• Disc Medicine may need to disclose the short-swing profit issue in its future filings.

Key Dates